Retrospective Study
Copyright ©The Author(s) 2023.
World J Psychiatry. Dec 19, 2023; 13(12): 1037-1045
Published online Dec 19, 2023. doi: 10.5498/wjp.v13.i12.1037
Table 1 Clinical characteristics of study subjects [n (%)], M (P25, P75)
Clinical characteristics
Western medicine (n = 43)
Combination (n = 43)
χ2/t
P value
Sex0.4270.514
    Man26 (60.50)23 (53.50)
    Woman17 (39.50)20 (46.50)
Age (yr)58.53 ± 5.1659.12 ± 5.04-0.5280.599
Herpes zoster disease course (d)5.00 (4.00, 6.00)5.00 (4.00, 6.00)-0.3170.751
Residence0.1870.665
    Town19 (44.20)21 (48.80)
    City 24 (55.80)22 (51.20)
Years of education 0.4660.792
    < 98 (18.60)10 (23.30)
    9-1224 (55.80)21 (48.80)
    > 1211 (25.60)12 (27.90)
Table 2 The pain scores between the two groups, M (P25, P75)
Group
Pre-treatment
Post-treatment
Z
P value
Western medicine (n = 43)7.00 (6.00, 8.00)4.00 (4.00, 5.00)-6.801< 0.001
Combination (n = 43)7.00 (6.00, 8.00)4.00 (3.00, 4.00)-7.960< 0.001
Z-0.448-3.825
P value0.654< 0.001
Table 3 Effectiveness of herpes zoster treatment, n (%)
Group
Remarkable effect
Effective
Ineffective
Western medicine (n = 43)11 (25.58)22 (51.16)10 (23.26)
Combination (n = 43)19 (44.19)18 (41.86)6 (13.95)
Z-2.144
P value0.032
Table 4 Comparison of adverse reactions produced by different treatment regimens, n (%)
Group
Headache
Blurred vision
Nausea
Emesis
Others
Total
Western medicine (n = 43)5 (11.63)2 (4.65)6 (13.95)3 (6.98)3 (6.98)17 (39.53)
Combination (n = 43)2 (4.65)1 (2.33)4 (9.30)1 (2.33)3 (6.98)8 (18.60)
χ24.568
P value0.033